Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- delavirdine
- lazertinib
Interactions between your drugs
delavirdine lazertinib
Applies to: delavirdine, lazertinib
Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of lazertinib. To examine this interaction, healthy adult participants (n=16) received lazertinib (160 mg) on day 1, then the potent CYP450 3A4 inhibitor itraconazole (200 mg) daily on days 8 to 16. On day 12, the participants received another single dose of lazertinib (160 mg). Concomitant use of itraconazole increased lazertinib's peak plasma concentration (Cmax) and systemic exposure (AUC) by 1.2- and 1.5-fold, respectively. The clinical significance of these changes is unknown.
References (3)
- (2024) "Product Information. Lazcluze (lazertinib)." Janssen Biotech, Inc.
- Janssen Research & Development, LLC (2024) A study to assess the effects of itraconazole and rifampin on lazertinib in healthy adult participants. https://clinicaltrials.gov/study/NCT04410094?tab=table
- Mehta J, Haddish-Berhane N, Hellemans P, et al. (2024) PI-100-The drug-drug interaction (DDI) effect of steady state itraconazole exposure on single dose pharmacokinetics (PK) of lazertinib. https://ascpt2023.eventscribe.net/fsPopup.asp?efp=T0ZZRlFOUkgxODIxOQ&PosterID=553886&rnd=0.9604228&mode=posterInfo
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Cabenuva
Cabenuva (cabotegravir and rilpivirine) injections are a long-acting HIV treatment used to keep HIV ...
Biktarvy
Biktarvy is a complete HIV-1 treatment in a once-a-day single tablet containing three antiviral ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Descovy
Descovy is used to treat and prevent HIV infection in adults and adolescents. When used for HIV-1 ...
Dovato
Dovato is a complete HIV-1 treatment regimen in one tablet that may be used in adults and children ...
Truvada
Truvada is used to prevent HIV (HIV PrEP) or treat HIV-1 infection in combination with other HIV-1 ...
Atripla
Atripla prevents the human immunodeficiency virus (HIV) from reproducing in your body. Learn about ...
Isentress
Isentress is used to treat HIV, which causes acquired immunodeficiency syndrome (AIDS). Learn about ...
Viread
Viread (tenofovir) is used to treat HIV, which causes the acquired immunodeficiency syndrome ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.